Banyan Group

Banyan Biomarkers is a specialized biotechnology company focused on the development and commercialization of diagnostic tests for traumatic brain injury (TBI). The company achieved a significant milestone by receiving FDA de novo clearance for the Banyan Brain Trauma Indicator, the first blood-based diagnostic test designed to aid in the evaluation of mild TBI, commonly known as concussion. Their technology identifies specific protein biomarkers, namely UCH-L1 and GFAP, which are released into the bloodstream following a brain injury. By providing an objective measure of brain trauma, Banyan Biomarkers aims to reduce the reliance on CT scans and improve the speed and accuracy of diagnosis in emergency settings. The company continues to collaborate with military and clinical partners to expand the utility of its biomarker platform.